700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Case Report Open Access
In current healthcare provision there is an ever growing focus on acquisition cost of pharmacological interventions, and whether they represent value for money. It is often forgotten that for every “breakthrough” drug that makes it onto our formularies, approximately 1000 never get beyond phase 1 clinical trials. Even once this hurdle is passed, there are many more obstacles that stand in the way of a new medication ever being prescribed. The cost of the development of these failed medications is incorporated into the cost of every new product that is brought to market, therefore, every effort is made to ensure, once a product gets to the final stages of development it is used in the most appropriate population using the most appropriate outcomes in order to demonstrate its maximal efficiency.